These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6512004)

  • 1. Attenuation by pergolide of haloperidol-induced striatal dopamine receptor density.
    Koller WC
    J Clin Psychopharmacol; 1984 Dec; 4(6):343-5. PubMed ID: 6512004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission.
    Calabresi P; De Murtas M; Mercuri NB; Bernardi G
    Ann Neurol; 1992 Apr; 31(4):366-73. PubMed ID: 1350190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of the changes in striatal acetylcholine levels induced by pergolide and haloperidol after lesion of the nigrostriatal dopaminergic pathways in the rat.
    Fage D; Guerin B; Feuerstein C; Demenge P; Scatton B
    Brain Res; 1984 Sep; 310(2):379-83. PubMed ID: 6488029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
    Schweitzer JW; Schwartz R; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine binding following prolonged haloperidol pretreatment.
    Hitri A; Weiner WJ; Borison RL; Diamond BI; Nausieda PA; Klawans HL
    Ann Neurol; 1978 Feb; 3(2):134-40. PubMed ID: 655662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
    Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
    Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive periods for the effect of haloperidol on development of striatal dopamine receptors.
    Rosengarten H; Friedman E; Friedhoff AJ
    Birth Defects Orig Artic Ser; 1983; 19(4):511-3. PubMed ID: 6871420
    [No Abstract]   [Full Text] [Related]  

  • 10. Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa.
    Friedhoff AJ; Bonnet K; Tosengarten H
    Res Commun Chem Pathol Pharmacol; 1977 Mar; 16(3):411-23. PubMed ID: 847296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of pergolide on the kinetics of the dopamine receptors in the corpus striatum of the rat].
    Jiang DH
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):209-13. PubMed ID: 4075909
    [No Abstract]   [Full Text] [Related]  

  • 12. Interaction of pergolide with central dopaminergic receptors.
    Goldstein M; Lieberman A; Lew JY; Asano T; Rosenfeld MR; Makman MH
    Proc Natl Acad Sci U S A; 1980 Jun; 77(6):3725-8. PubMed ID: 6932044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM; Matvienko OA; Nurk AM
    Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum.
    Reches A; Wagner HR; Jackson-Lewis V; Yablonskaya-Alter E; Fahn S
    Neurology; 1984 Sep; 34(9):1208-12. PubMed ID: 6540406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
    Schröder U; Schröder H; Augustin W; Sabel BA
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites.
    Wong DT; Threlkeld PG; Bymaster FP
    Arzneimittelforschung; 1993 Apr; 43(4):409-12. PubMed ID: 7684223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ethanol and haloperidol on dopamine receptor (D2) density.
    Fuchs V; Coper H; Rommelspacher H
    Neuropharmacology; 1987 Aug; 26(8):1231-3. PubMed ID: 3658125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro.
    Meller E; Bohmaker K; Goldstein M; Schweitzer JW; Friedhoff AJ
    Eur J Pharmacol; 1985 Mar; 109(3):389-94. PubMed ID: 3157587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.